OncoMatch/Clinical Trials/NCT05948033
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
Is NCT05948033 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CD70-targeting CAR-T cells for lymphoma.
Treatment: CD70-targeting CAR-T cells — In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma . In this clinical trial, at least 12 eligible patients in dose escalation period will be enrolled to receive 3 doses of CD70-CAR cell therapy according to the "3+3" principle. In dose expansion period, additional at most 21 eligible patients will be enrolled to receive CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Biomarker criteria
Required: CD70 antigen expression percentage ≥ 10% (≥ 10%)
CD70 antigen expression percentage ≥ 10%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy
Relapse after treatment with ≥2 lines systemic therapy for all the above disease types. Relapse disease is defined as disease progression after last regimen.
Must have received: autologous stem cell transplant
Refractory post-autologous stem cell transplant (ASCT)...
Cannot have received: CD70-targeted therapy
Previously received targeting CD70 therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
anc ≥1×10^9/l; platelet count ≥50×10^9/l; hemoglobin ≥80 g/l
Kidney function
serum creatinine ≤1.5xuln
Liver function
serum ast and serum alt ≤3.0 x uln (≤5 x uln for patients with liver metastases); total serum bilirubin ≤3.0 x uln
Cardiac function
echocardiography showed left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05948033 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD70-targeted therapy, allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Does this trial require CD70?
Yes, CD70 antigen expression percentage ≥ 10% is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages